Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-134935

Published: 2020

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Blood (2019) 134 (Supplement_1): 3152.

https://doi.org/10.1182/blood-2019-123560

Published: 2019

Journal Articles

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Noam Benyamini, MD, Adir S, MD, Moshe E. Gatt, MD, Yael C Cohen, MD, Irit Avivi, MD, Svetlana Trestman, MD, Olga Shvetz, MD, Tamar Tadmor, MD, Najib Dally, MD, Yevgeny Chober, Hila Magen, MD, Chezi Ganzel, MD, Osnat Jarchowcky Dolberg, Celia Suriu, MD, Noa Lavi, MD

Blood (2018) 132 (Supplement 1): 3259.

https://doi.org/10.1182/blood-2018-99-115985

Published: 2018

Journal Articles

Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs)

Katia Beider, Evgenia Rosenberg, Valeria Voevoda, Hanna Bitner, Yaarit Sirovsky, Hila Magen, MD, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Michael Milyavsky, PhD, Amnon Peled, Arnon Nagler, MD

Blood (2018) 132 (Supplement 1): 1366.

https://doi.org/10.1182/blood-2018-99-114652

Published: 2018

Journal Articles

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

Yael C Cohen, Hila Magen, MD, Noa Lavi, MD, Moshe E. Gatt, MD, Evgeni Chubar, MD, Natalia Kreiniz, Tamar Tadmor, MD, Svetlana Trestman, MD, Roy Vitkon, MD, Ory Rouvio, Olga Shvetz, MD, Adir Shaulov, MD, Irit Avivi, MD

Blood (2018) 132 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2018-99-114217

Published: 2018

Journal Articles

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma

Timothy Brighton, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, David Ghez, Brendan M. Weiss, MD, Andreas Kirsch, Hila Magen, MD, Mercedes Gironella, Dra., Albert Oriol, MD, Matthew Streetly, BMBS, MRCP, MRCPath, Xiang Qin, Rajesh Bandekar, Peter Hu, Ming Qi, MD PhD, Sepideh Nemat, MD PhD, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 3155.

https://doi.org/10.1182/blood.V130.Suppl_1.3155.3155

Published: 2017

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Philippe Moreau, MDPhD, Albert Oriol, MD, Jonathan L. Kaufman, MD, Heather Sutherland, MD, Marc Lalancette, MD FRCP, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, MD PhD, Miles Prince, MD FRACP, FRCPA, Tara Cochrane, Lisa O'Rourke, MSN, RN, Kaida Wu, Jordan M. Schecter, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1883.

https://doi.org/10.1182/blood.V130.Suppl_1.1883.1883

Published: 2017

Journal Articles

Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-Induced ER Stress and Cell Death Via HSP70 and LAMP3 Down-Regulation: Novel Therapeutic Target for Multiple Myeloma

Katia Beider, Valeria Voevoda, Hanna Bitner, Evgenia Rosenberg, Yaarit Sirovsky, Hila Magen, MD, Olga Ostrovsky, PhD, Avichai Shimoni, MD, Zohar Bromberg, PhD, Amnon Peled, Arnon Nagler, MD

Blood (2017) 130 (Supplement 1): 804.

https://doi.org/10.1182/blood.V130.Suppl_1.804.804

Published: 2017

Journal Articles

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

Chezi Ganzel, Ory Rouvio, MD, Hila Magen, MD, Osnat Jarchowsky, Irit Avivi, MD, Katrin Herzog, Cohen Yossi, Tamar Tadmor, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Arnon Nagler, MD MSc, Yael Cohen, MD, Shlomo Bulvik, MD, Dina Ben Yehuda, MD, Jacob M. Rowe, MD, Moshe E. Gatt, MD

Blood (2016) 128 (22): 5699.

https://doi.org/10.1182/blood.V128.22.5699.5699

Published: 2016

Journal Articles

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

Philippe Moreau, Jonathan L. Kaufman, MD, Heather J. Sutherland, MD PhD, Marc Lalancette, MDFRCP-C, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, Miles Prince, MD, Tara Cochrane, Nushmia Z Khokhar, Mary Guckert, Xiang Qin, Albert Oriol

Blood (2016) 128 (22): 489.

https://doi.org/10.1182/blood.V128.22.489.489

Published: 2016

Journal Articles

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

Yael Cohen, MD, Moshe E. Gatt, MD, Noa Lavi, MD, Chezi Ganzel, Hila Magen, MD, Irit Avivi, MD, Tamar Tadmor, MD, Celia Suriu, MD, Osnat Jarchowsky Dolberg, Amitai Papushado, MD, Svetlana Trestman, MD, Ron Ram, MD

Blood (2016) 128 (22): 4510.

https://doi.org/10.1182/blood.V128.22.4510.4510

Published: 2016

Journal Articles

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis

Katia Beider, PhD, Valeria Voevoda, Hanna Bitner, Evgenia Rosenberg, Hila Magen, MD, Olga Ostrovsky, PhD, Merav Leiba, MD, Noya Shilo, MD, Avichai Shimoni, MD, Michael Milyavsky, PhD, Amnon Peled, PhD, Arnon Nagler

Blood (2016) 128 (22): 891.

https://doi.org/10.1182/blood.V128.22.891.891

Published: 2016

Journal Articles

Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study

Monica Galli, MD, Hila Magen, MD, Hermann Einsele, Manik Chatterjee, MD, Mariella Grasso, MD, Giorgina Specchia, Paola Barbieri, MD, David Paoletti, MS, Silvia Pace, MS, Ralph D Sanderson, PhD, Alessandro Rambaldi, MD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 3246.

https://doi.org/10.1182/blood.V126.23.3246.3246

Published: 2015

Journal Articles

Uninvolved Immunoglobulins Predicting Hematological Response in Newly Diagnosed AL Amyloidosis

Eli Muchtar, MD, Hila Magen, MD, Gilad Itchaki, MD, Amos Cohen, MD, Raama Rosenfeld, Tzippy Shochat, MSc, Ran Kornowski, MD, Zaza Iakobishvili, MD, Pia Raanani, MD

Blood (2015) 126 (23): 4262.

https://doi.org/10.1182/blood.V126.23.4262.4262

Published: 2015

Journal Articles

Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience

Eli Muchtar, MD, Adi Zelig, Eyal Robenshtok, MD, Tzippy Shochat, MSc, Nino Oniashvili, PhD, Irina Amitai, MD, Pia Raanani, MD, Hila Magen, MD

Blood (2015) 126 (23): 5386.

https://doi.org/10.1182/blood.V126.23.5386.5386

Published: 2015

Journal Articles

Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study

Eli Muchtar, MD, Moshe Gatt, MD, Ory Rouvio, Chezi Ganzel, Evgeni Chubar, MD, Celia Suriu, MD, Tamar Tadmor, Olga Shevetz, MD, Noa Lavi, MD, Tzippy Shochat, MSc, Yael C Cohen, MD, Irit Avivi, MD, Pia Raanani, MD, Hila Magen, MD

Blood (2015) 126 (23): 5371.

https://doi.org/10.1182/blood.V126.23.5371.5371

Published: 2015

Journal Articles

Efficacy and Safety of Autologus Hematopoietic Cell Transplantation in Elderly Patients with Multiple Myeloma: A Retrospective Israeli Multi-Site Cohort Study

Yael C Cohen, MD, Tsila Zuckerman, MD, Moshe Yeshurun, MD, Galit Perez, MD, Hila Magen, MD, Israel Henig, MD, Itai Levi, MD, Liat Shargian, Svetlana Trestman, MD, Uri Rouvio, MD, Elizabeth Naparstek, MD, Eti Ganon-Elazar, PhD, Irit Avivi, MD, Ron Ram, MD

Blood (2014) 124 (21): 3989.

https://doi.org/10.1182/blood.V124.21.3989.3989

Published: 2014

NARROW

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Real-Life Data on the Outcome of Daratumomab-Refractory Myeloma Patients: Multi-Center Experience

Inhibition of WIP1 Phosphatase in Multiple Myeloma Overcomes Bortezomib Resistance and Promotes Cell Death Via ER Stress-Induced Apoptotic JNK/c-Jun Signaling and Downregulation of Inhibitors of Apoptosis Proteins (IAPs)

Time to Progression Post-Induction Predicts Outcomes of Ixazomib Based Therapy for Relapsed/Refractory Myeloma: Real World Data from a Multi-Site Israeli Registry Study

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Patients with High-Risk Smoldering Multiple Myeloma

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Blocking of Transient Receptor Potential Vanilloid1 (TRPV1) Promotes Lysosomal Destabilization and Enhances Bortezomib-Induced ER Stress and Cell Death Via HSP70 and LAMP3 Down-Regulation: Novel Therapeutic Target for Multiple Myeloma

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

Treatment Patterns and Clinical Outcomes in High-Risk Multiple Myeloma Patients Carrying the 17p Deletion: A Multi-Center Retrospective Observational Study

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis

Roneparstat (SST0001), an Innovative Heparanase (HPSE) Inhibitor for Multiple Myeloma (MM) Therapy: First in Man Study

Uninvolved Immunoglobulins Predicting Hematological Response in Newly Diagnosed AL Amyloidosis

Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience

Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study

Efficacy and Safety of Autologus Hematopoietic Cell Transplantation in Elderly Patients with Multiple Myeloma: A Retrospective Israeli Multi-Site Cohort Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only